A Phase 2 Trial to Study Efficacy and Safety of HBI0101 (NXC-201) CART in Subjects With Multiple Myeloma and Light-Chain Amyloidosis
Latest Information Update: 20 May 2025
At a glance
- Drugs NXC 201 (Primary)
- Indications Amyloid light-chain amyloidosis; Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 20 May 2025 New trial record